Curis (CRIS) AI Stock Analysis

• Market Cap: $29.29M
• Dividend Yield: N/A
• Average Volume (3M): 95.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.91
• Revenue Growth: 14.17%
• EPS Growth: 28.26%
• Country: US
• Employees: 34
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): 1.25
• Shares Outstanding: 10,462,250
• 10 Day Avg. Volume: 102,148
• 30 Day Avg. Volume: 95,858
• PEG Ratio: -0.05
• Price to Book (P/B): 1.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.94
• Enterprise Value/Market Cap: 1.31
• Enterprise Value/Revenue: 0.90
• Enterprise Value/Gross Profit: 3.46
• Enterprise Value/Ebitda: -0.21
• 1Y Price Target: $14.50
• Price Target Upside: 423.47% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 53 Neutral
• Price Target: $3.00 ▲(8.30%Upside)

Curis' overall score reflects a blend of promising clinical trial results and significant financial challenges. The company's advancement in clinical studies provides growth potential, but persistent operational losses and a limited cash runway are pressing concerns. Technical indicators suggest short-term momentum, yet valuation remains unattractive due to a lack of profitability.

Positive Factors

Clinical Development

Emavusertib is the only IRAK4 inhibitor in late-stage clinical development, positioning it uniquely in a crowded market.

Regulatory Support

Curis has received a positive regulatory foundation from both FDA and EMA, enhancing its potential market success.

Negative Factors

Enrollment Challenges

The primary challenge is the difficulty of enrollment, given the small patient population.

Stock Valuation

The price target is being lowered due to dilution from a recent raise, which could impact the stock's valuation.

Curis Business Overview & Revenue Model

Company Description

Curis, Inc. (CRIS) is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. The company is engaged in the research and development of drug candidates aimed at addressing unmet medical needs in oncology. Curis leverages its scientific expertise in small molecule drug discovery and development to advance its pipeline of proprietary drug candidates.

How the Company Makes Money

Curis primarily makes money through the development and commercialization of its proprietary drug candidates, focusing on oncology therapies. The company generates revenue from strategic collaborations and licensing agreements with pharmaceutical and biotechnology firms, which may include upfront payments, milestone payments, and royalties on product sales. Additionally, Curis may receive research and development funding from partners to support its clinical trials and drug development efforts. The company's revenue model heavily relies on successful clinical trial outcomes and obtaining regulatory approval for its drug candidates.

Curis Financial Statement Overview

Summary

Curis faces significant financial challenges with persistent losses and negative cash flows. Revenue growth is evident, but the company struggles with profitability and a fragile balance sheet, indicated by negative equity and ongoing operational losses.

Income Statement

Curis shows a slight increase in revenue from the previous year, but the company still suffers from significant negative net income and EBIT margins, indicating ongoing profitability issues. The gross profit margin remains positive, but the net profit margin is deeply negative, reflecting operational challenges.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, which is concerning, indicating that liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity. This highlights potential solvency issues and financial instability.

Cash Flow

Curis has negative free cash flow and operating cash flow, which are troubling. The cash flow from operations is consistently negative, which may indicate difficulties in generating cash from core activities. Despite some improvement in cash flow from investing activities, the overall cash flow position remains weak.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
11.20M	10.91M	10.02M	10.16M	10.65M	10.84M
	Gross Profit
11.12M	10.81M	9.81M	9.90M	10.12M	10.30M
	EBIT
-42.23M	-44.54M	-48.33M	-53.02M	-42.06M	-24.90M
	EBITDA
-41.87M	-42.57M	-45.14M	-50.51M	-39.98M	-24.67M
	Net Income Common Stockholders
-42.13M	-43.39M	-47.41M	-60.32M	-50.64M	-34.88M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
20.28M	20.00M	56.33M	85.62M	139.85M	183.06M
	Total Assets
39.33M	41.27M	77.28M	108.85M	162.30M	204.36M
	Total Debt
2.64M	2.95M	2.79M	6.74M	5.04M	7.66M
	Net Debt
-17.64M	-17.04M	-23.89M	-12.92M	-34.97M	-121.95M
	Total Liabilities
45.93M	47.26M	57.61M	62.30M	71.59M	73.69M
	Stockholders Equity
-6.61M	-6.00M	19.67M	46.55M	90.71M	130.67M
Cash Flow		Free Cash Flow
-33.58M	-39.56M	-38.43M	-54.75M	-37.62M	-26.42M
	Operating Cash Flow
-33.58M	-39.56M	-38.43M	-54.34M	-37.62M	-25.74M
	Investing Cash Flow
10.53M	29.44M	37.79M	33.02M	-47.90M	-49.05M
	Financing Cash Flow
13.38M	3.44M	7.58M	867.00K	-4.17M	188.81M

Curis Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.77
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRIS, the sentiment is Positive. The current price of 2.77 is above the 20-day moving average (MA) of 2.27, above the 50-day MA of 1.91, and below the 200-day MA of 3.47, indicating a neutral trend. The MACD of 0.18 indicates Negative momentum. The RSI at 70.26 is Negative, neither overbought nor oversold. The STOCH value of 67.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRIS.

Curis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
CRIS	53 Neutral	$29.29M	―	-2951.24%	―	14.17%	28.26%
VVOS	47 Neutral	$12.43M	―	-450.47%	―	9.47%	81.37%
LSTA	43 Neutral	$22.18M	―	-56.49%	―	―	7.07%
BCAB	35 Underperform	$28.35M	―	-246.21%	―	―	44.38%
UBX	31 Underperform	$15.14M	―	-231.27%	―	―	35.08%
CVM	27 Underperform	$12.73M	―	-238.64%	―	―	30.96%

Curis Corporate Events

Curis Approves Key Amendments at Annual Meeting

On May 20, 2025, Curis, Inc. held its Annual Meeting of Stockholders virtually, where several key amendments were approved. The stockholders approved an amendment to the company’s stock incentive plan to reserve an additional 1,255,000 shares of common stock, increasing the total authorized shares for issuance. Additionally, an amendment to the company’s Restated Certificate of Incorporation was adopted, increasing the number of authorized shares of capital stock and common stock significantly. The board also approved changes to the company’s bylaws, reducing the quorum requirement for stockholder meetings. These changes aim to enhance the company’s operational flexibility and shareholder engagement.

The most recent analyst rating on (CRIS) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.